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Abstract: Tafenoquine (TQ), a new synthetic analog of primaquine, has relatively poor 
bioavailability and associated toxicity in glucose-6-phosphate dehydrogenase (G6PD)-deficient 
individuals. A microemulsion formulation of TQ (MTQ) with sizes 20 nm improved the 
solubility of TQ and enhanced the oral bioavailability from 55% to 99% in healthy mice (area 
under the curve 0 to infinity: 11,368±1,232 and 23,842±872 min⋅µmol/L) for reference TQ and 
MTQ, respectively. Average parasitemia in Plasmodium berghei-infected mice was four- to 
tenfold lower in the MTQ-treated group. In vitro antiplasmodial activities against chloroquine-
sensitive and chloroquine-resistant strains of Plasmodium falciparum indicated no change in half 
maximal inhibitory concentration, suggesting that the microemulsion did not affect the inherent 
activity of TQ. In a humanized mouse model of G6PD deficiency, we observed reduction in 
toxicity of TQ as delivered by MTQ at low but efficacious concentrations of TQ. We hereby 
report an enhancement in the solubility, bioavailibility, and efficacy of TQ against blood stages 
of Plasmodium parasites without a corresponding increase in toxicity.
Keywords: microemulsion, solubility, G6PD deficiency, in vivo efficacy
Introduction
Malaria, caused by parasites of the genus Plasmodium, is one of the world’s deadliest 
infectious diseases. In 2012, approximately 627,000 malaria deaths occurred 
worldwide and 3.4 billion people were at risk of contracting malaria.1 Over 90% of 
malaria-associated deaths occur in Sub-Saharan Africa, with 77% of deaths occurring in 
children under the age of 5 years. On average, a child dies of malaria every 60 seconds, 
and children who survive the disease are at an increased risk of long-term neurological 
and cognitive disabilities.2 Malaria, therefore, has a huge societal and economic impact 
globally and particularly in Sub-Saharan Africa.
Drug treatment remains the mainstay for the treatment of malaria as there is at present 
no effective vaccine. Currently used antimalarial drugs include 4-aminoquinolines, 
arylaminoalcohols, 8-aminoquinolines, artemisinins, antifolates, respiratory chain 
inhibitors, and antibiotics.3 Even though these drugs are available, there has been a failure 
to eradicate malaria, partially because of the limitations of these drugs.4 Such limitations 
include a short half-life, erratic absorption, and poor oral bioavailability, which can 
result in treatment failure; the use of high dosages and dose frequency; toxicity leading 
to poor patient compliance; and development of drug resistance. Nanoparticle drug 
delivery systems using microemulsions have the potential to improve drug therapeutic 
properties and enhance bioavailability by improving solubility of the drugs.5 This will 
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enable the drug to remain in the dissolved state for enhanced 
absorption, possibly altering the pharmacokinetic parameters 
of the drug molecule which ultimately enhances drug potency 
and influences toxicity. 
The 8-aminoquinolines, such as primaquine (PQ) and 
tafenoquine (TQ), have unique modes of action and have the 
ability to prevent relapses caused by Plasmodium vivax and 
Plasmodium ovale. Research has shown that TQ has several 
advantages over PQ; for example, the in vitro activity of TQ 
is 4 to 100 times higher than PQ while the half-life is 50 times 
longer.6,7 TQ is also an effective transmission blocking agent,8 
has a long half-life of approximately 14 days,9 and acts on all 
stages of Plasmodium falciparum infection.10–12 However, it 
has relatively poor aqueous solubility, which affects its oral 
bioavailability and the treatment dose. Studies have demon-
strated the efficacy of a 200 mg or 400 mg dose when admin-
istered weekly for 13 weeks as a prophylactic measure,13 or 
a 400 mg dose per month given over a period of 6 months.14 
However, the relatively high doses of drug required for efficacy 
has resulted in various adverse effects, among them gastro-
intestinal disturbances and hemolysis in glucose-6 phosphate 
dehydrogenase (G6PD)-deficient individuals.13,15  Approxi-
mately 400 million people worldwide are estimated to be 
G6PD deficient,16 and this deficiency is quite common in popu-
lations in malaria-endemic regions.17 A recent study reported 
a comparable loss of G6PD-deficient human red blood cells 
(HuRBCs) in mouse models treated with PQ and those treated 
with either pamaquine, sitamaquine, TQ, or dapsone, all of 
which are known to induce hemolytic toxicity.18 We envisage 
that enhancing the solubility of TQ in a microemulsion could 
lead to a reduction in toxicity and hence a reduction in the 
rate at which hemolysis occurs in G6PD-deficient individuals. 
Reduction in dose and dose frequency could be achieved by 
enhancing the pharmacokinetic properties of TQ. Over the past 
20 years, researchers have reported the therapeutic enhancing 
properties of microemulsions,19–21 but this system has not been 
widely applied for malaria treatment. 
In the present study, we report on the development 
of a novel microemulsion of TQ (MTQ) (sizes 20 nm), 
enhancement in the pharmacokinetic and therapeutic efficacy 
of MTQ relative to unformulated TQ (RTQ), as well as 
the comparative evaluation of the toxicity of MTQ in a 
humanized nonobese diabetic (NOD) severe combined immu-
nodeficiency (SCID) mouse model with G6PD deficiency. 
Methods
Formulation of MTQ
TQ, sodium oleate, Tween 80, polyvinyl alcohol (PVA), and 
ethanol were purchased from Sigma Aldrich Co (St Louis, 
MO, USA). Citronella essential oil was supplied by SOIL 
(KwaZulu-Natal, South Africa). Oil-in-water (o/w) micro-
emulsions loaded with or without TQ were prepared by 
combining a nonionic surfactant and a long-chain carbon fatty 
acid ester as depicted in Table 1. An aqueous solution of a 
mixture of 1% w/v PVA and sodium oleate (0.2% w/v) was 
prepared in a volume ratio of 1:1. To this was added, dropwise, 
an ethanolic solution containing TQ (concentration: 1.25 or 
0.625 or 0.125 mg/mL) and the oil phase (citronella oil). 
Thereafter, 50 µL of Tween 20 or Tween 80 were introduced 
to the mixture while stirring. The admixture was then heated 
to 60°C and maintained at this temperature for 5 minutes, fol-
lowed by a quenching process at ambient temperature, thereby 
producing spontaneously a transparent microemulsion.
characterization of size, size distribution, and zeta 
potential of microemulsion
The average droplet size, size distribution, and zeta potential 
were measured by dynamic light scattering techniques using a 
Malvern Zetasizer Nano ZS (Malvern Instruments, Malvern, 
UK). Measurements were conducted on undiluted samples 
Table 1 Matrix of experiments for the preparation of microemulsions
Experiment 
number
 Parameters
Polyvinyl alcohol 
concentration
Na oleate 
concentration
Tween 
type
Tween 
volume
Essential  
oil volume
Temperature Ethanol
1 1 1 1 1 1 1 1
2 1 1 1 2 2 2 2
3 1 2 2 1 1 2 2
4 1 2 2 2 2 1 1
5 2 1 2 1 2 1 2
6 2 1 2 2 1 2 1
7 2 2 1 1 2 2 1
8 2 2 1 2 1 1 2
Notes: PVa concentration =1% w/v (level 1) and 2% (level 2). Na oleate concentration =0.1% w/v (level 1) and 0.2% w/v (level 2). Tween surfactance type =20 (level 10) 
and 80 (level 2). Tween volume =140 µl (level 1) and 280 µl (level 2). essential oil volume =0 µl (level 1) and 75 µl (level 2). Temperature =40°c (level 1) and 60°c (level 2). 
ethanol =1 ml (level 1) and 2 ml (level 2).
Abbreviations: PVa, polyvinyl alcohol; v, volume; w, weight.
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at 25°C at an angle of 173°. The intensity-weighted mean 
value was measured as the average of three independent 
measurements.
ph and conductivity
The pH values of the microemulsions were determined at 
ambient temperature. The conductivity of each microemul-
sion was measured by using a conductivity/TDS/salinity 
RS232 meter (model AZ-8306; AZ Instruments Corp., 
Taichung City, Taiwan) at 25°C. 
Drug solubility
TQ solubility was evaluated in the microemulsion formula-
tion and in the individual ingredients of the microemulsion. 
TQ was added in excess to the optimized microemulsion 
formulation as well as each individual ingredient in the for-
mulation. Maximum solubility of TQ in dimethyl sulfoxide 
of 5 mg/mL was used as reference concentration. After 
continuous shaking (100 rpm) for 24 hours at 37°C, samples 
were withdrawn and centrifuged at 10,000× g for 10 minutes. 
The supernatant was collected and diluted up to 40-fold with 
dimethyl sulfoxide. TQ concentration was then determined 
by ultraviolet spectrometry and absorbance was measured 
at 376 nm. The solubility of TQ in the microemulsion was 
compared to TQ solubility in the individual ingredients.
Parasitology
All the parasites used for this experiment were P. falciparum 
NF54 (MRA-1000, MR4; American Type Culture Collection 
[ATCC], Manassas, VA, USA) and Dd2 (MRA-156, MR4; 
ATCC). The asexual erythrocytic stages of these parasites 
were maintained in a continuous culture using the method 
of Trager and Jensen.22
In vitro antiplasmodial assay
The antiplasmodial activities of RTQ and MTQ were 
evaluated against the chloroquine (CQ)-sensitive (NF54) 
and CQ-resistant (Dd2) strains of P. falciparum. Quanti-
tative assessment of antiplasmodial activity in vitro was 
determined via the parasite lactate dehydrogenase assay 
as described in the literature.23 CQ was used as the refer-
ence drug. A full dose–response was performed for all 
compounds to determine the concentration inhibiting 50% 
of parasite growth (IC
50
 value). Samples were tested over 
a concentration range of 1,000–2 ng/mL (the initial con-
centration was 1000 ng/mL and the final concentration was 
2 ng/mL). The IC
50
 values were obtained using a nonlinear 
dose–response curve fitting analysis via GraphPad Prism 
v 4.0 software. 
In vivo pharmacokinetic and efficacy 
studies
animals
C57/BL6 mice (females 8–12 weeks) weighing 25–30 g 
were used. Mice were housed in 27×21×18 cm cages, under 
controlled environmental conditions (26°C±1°C, 60%±5% 
relative humidity, and a 12-hour light/dark cycle). Their diet 
consisted of standard laboratory food. Water was available ad 
libitum throughout the experiment. All studies and procedures 
were conducted with prior approval of the Ethics Committee 
of the University of Cape Town, Cape Town, South Africa 
(approval number 012/050) in accordance with the National 
Code for animal use in research, education, diagnosis, and 
testing of drugs and related substances in South Africa. 
Pharmacokinetic studies
Oral drug administration
The bioavailability of TQ was evaluated in whole blood 
samples after oral administration of the RTQ formula-
tion and MTQ formulation in a randomized, single-blind, 
parallel-group study. The RTQ formulation was prepared 
in 0.01 M HCl.
A study was conducted in eight mice, randomly divided 
into two groups (four mice per group), with the reference 
group receiving RTQ and the microemulsion group receiv-
ing MTQ containing the same dosage, namely 20 mg/kg TQ, 
via oral gavage. Blood samples (50 µL) were collected via 
tail-bleeding pre-dose and at 2, 8, 12, 24, 48, 72, 120, and 
168 hours post-dose in 0.5 mL lithium heparin microvials 
to prevent blood coagulation. 
Intravenous drug administration
The RTQ, which is the reference formulation, was admin-
istered intravenously at a dose of 2 mg/kg in 0.01 M HCl 
(n=5). Blood samples (50 µL) were collected via tail-bleeding 
pre-dose and at 0.17, 0.5, 1, 3, 5, 7, 12, and 24 hours post-
dose in 0.5 mL lithium heparin microvials to prevent blood 
coagulation. 
liquid chromatography–mass spectrometry (lc/Ms/Ms) 
assay
The concentrations of TQ were determined using a validated 
quantitative LC/MS/MS assay method developed in the 
Division of Clinical Pharmacology, University of Cape 
Town.  An optimized liquid–liquid extraction method was 
developed for the extraction of TQ from 20 µL mouse whole 
blood samples, using a universal Britton–Robinson buffer 
(pH 7) containing the internal standard (mefloquine) and 
ethyl acetate. Acetonitrile and formic acid were purchased 
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from EMD Millipore (Billerica, MA, USA). The internal 
standard (mefloquine) was obtained from Toronto Research 
Chemicals (Toronto, Ontario, Canada). The organic phase 
was evaporated under nitrogen at room temperature for 
30 minutes. The dried samples were reconstituted with 
mobile phase and a 3 µL sample was injected onto the 
analytical column. Chromatography was performed on a 
Phenomenex Luna 5 µm PFP(2), 100 A, 50×2 mm analytical 
column (Phenomenex, Torrance, CA, USA) using ace-
tonitrile and 0.1% formic acid (80:20, v/v) as mobile phase 
at a flow rate of 0.3 mL/min. An AB Sciex API 2000 mass 
spectrometer was operated at unit resolution in the multiple 
reaction monitoring mode monitoring the transition of the 
protonated molecular ions at 464.2 to the product ions at 
86.0 for TQ and the protonated molecular ions at 379.2 to 
the product ions at 361.1 for the mefloquine internal stan-
dard. The assay was validated over a range of 11.72 ng/mL 
to 3,000 ng/mL for TQ. The reliability of the assay was 
monitored at three levels with quality control samples. The 
limit of quantification for TQ was 11.72 ng/mL. Quadratic 
regression (1/x weighting) was used to construct calibra-
tion curves. The calibration standards and quality control 
standards were analyzed in duplicate in each study sample 
batch. The precision (total-assay coefficients of variation 
[%]) during sample analysis was less than 10% at high, 
medium, and low (2,400 ng/mL, 1,200 ng/mL, and 75 ng/
mL, respectively) quality control levels for TQ.
Data analysis
A nonlinear mixed-effects model was developed to describe TQ 
pharmacokinetics in mice. NONMEM software (version 7.2)24 
was used for model implementation, while Perl Speaks 
NONMEM,25 Xpose,26 and Pirana27 were used for model 
diagnostics and facilitation of the modeling process. Model 
development was guided by the NONMEM objective func-
tion value (assumed to be χ2-distributed), goodness-of-fit 
plots, and visual predictive checks.28 First-order absorption 
(for the oral data) and one- and two-compartment disposition 
models were investigated. An error structure with an additive 
and a proportional component was used, and data below the 
limit of quantification were imputed to half of the limit of 
quantification, but treated with a large, additive-only error 
component. Allometric scaling,29 based on each mouse body 
weight, was used to adjust clearance and volume parameters 
accounting for body size. The presence of between-subject 
variability in the model parameters was tested as lognormal 
distribution, and the value of oral bioavailability was 
investigated. Statistical differences between the particle 
sizes, IC
50
s, and pharmacokinetic values were compared by 
one-way analysis of variance with a Tukey’s post hoc test 
(with a level of significance P0.05). Table 2 shows the 
pharmacokinetic parameters evaluated from whole blood 
drug levels obtained.
Efficacy studies in Plasmodium berghei-infected mice
TQ was evaluated in a mouse model of malaria for in vivo 
efficacy. The efficacy of RTQ was compared to that of MTQ. 
Additionally, snapshot pharmacokinetic samples were col-
lected to determine the concentration of TQ at predetermined 
time intervals. The parasite used was the CQ-sensitive 
isolate P. berghei that expresses green fluorescent protein 
(GFP). Two host mice were infected with parasites and left 
untreated to allow the parasites to multiply. Parasitemia was 
monitored until it was sufficiently high; at that time, parasites 
were harvested from the host mice via cardiac puncture. The 
two parasite stocks were pooled and average parasitemia of 
the pooled stock was determined with the FACSCalibur™ 
using the software CellQuestPro.  Additionally, the total 
Table 2 summary of the pharmacokinetic parameters for rTQ and MTQ (IV n=5, oral n=4)
Pharmacokinetic 
parameter
RTQ formulation MTQ formulation 
IV administration (2 mg/kg) Oral administration (20 mg/kg) Oral administration (20 mg/kg)
Average SEM Average SEM Average SEM
cmax (µM) n/a n/a 3.06 0.37 5.82 0.26
Tmax (h) n/a n/a 9.0 1.0 6.5 1.5
apparent half-life (h) 43.7 1.5 38.3 4.1 44.7 1.3
Plasma cl (ml/min/kg) 1.84 0.07 n/a n/a n/a n/a
Vd (l/kg) 2.34 0.00 n/a n/a n/a n/a
Vss (l/kg) 6.81 0.00 n/a n/a n/a n/a
aUc0–inf (min⋅µmol/l) 2,363 146 11,368 1,232 23,842 872
Ba (%) n/a n/a 55 2 99 1.6
Abbreviations: aUc0–inf, area under the curve 0 to infinity; BA, bioavailability; CL, clearance; Cmax, peak concentration; h, hours; IV, intravenous; min, minutes; MTQ, 
microemulsion of tafenoquine; n/a, not applicable; rTQ, unformulated tafenoquine; seM, standard error of the mean; Tmax, time to peak concentration; Vd, volume of 
distribution; Vss, steady-state volume of distribution.
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number of erythrocytes per milliliter of the pooled stock 
was determined to ensure test animals obtained both uni-
form and correct amounts of parasite to establish the infec-
tion. Each mouse was infected with 1.5×107 parasitized red 
blood cells intraperitoneally. Once the malaria infection 
(parasitemia 5%) had been established in the mice, MTQ 
and RTQ were administered at four different concentrations 
(20 mg/kg, 10 mg/kg, 5 mg/kg, and 1 mg/kg). 
g6PD toxicity evaluation in scID mouse model
Experimentation was carried out at SUNY Upstate Medical 
University, Syracuse, NY, USA, where researchers have 
developed and validated a method to predict the hemolytic 
potential of drugs by using NOD SCID mice engrafted with 
African variant (A-) G6PD-deficient HuRBCs.18 Healthy 
NOD SCID mice (females 8–10 weeks) weighing approxi-
mately 20 g were used.  All studies and procedures were con-
ducted with prior approval of the Institutional Animal Care 
and Use Committee (IACUC) of SUNY Upstate Medical 
University (approval number 292) in accordance with the 
“Guide for care and use of laboratory animals”.30  Mice 
were housed in 27×21×18 cm cages, under controlled envi-
ronmental conditions (26°C±1°C, 60%±5% relative humid-
ity, and a 12-hour light/dark cycle). Their diet consisted of 
standard laboratory food. Water was available ad libitum 
throughout the experiment. This evaluation was carried out 
to assess and compare the hemolytic effects of 3-day treat-
ment regimens with TQ microemulsion at effective doses of 
10 mg/kg, 5 mg/kg, and 1 mg/kg (Table 3) on NOD SCID 
mice engrafted with A-G6PD-deficient HuRBCs. The NOD 
SCID mice received daily transfusions of HuRBCs from 
G6PD-deficient donors. To ascertain the hemolytic effect 
of MTQ and RTQ, comparable to reference control using 
PQ, two primary parameters, loss percent of HuRBC and 
percent murine reticulocyte (muRetic) levels, were evalu-
ated. PQ, RTQ, and MTQ were evaluated in NOD SCID 
mice (female), 9–11 weeks old, engrafted with A-G6PD-
deficient HuRBCs.
Drug preparation
For PQ, 10 mg (0.010 g) stock was weighed and reconsti-
tuted fresh daily in 1,000 µL phosphate-buffered saline. For 
TQ control, 5 mg TQ was weighed and reconstituted fresh 
daily in 500 µL hydroxyethyl cellulose–Tween. MTQ was 
prepared as stated in the Formulation of MTQ section.
engraftment and hemolysis assessment
All 29 mice were engrafted with 5×109 red blood cells 
intraperitoneally for 14 days. Twenty-eight mice met 
inclusion criteria (HuRBC 60%; mean: 72.2%). The 
first drug administration and assessment was carried out 
on day 15. Hemolysis was monitored on days 0, 4, and 7. 
The following were performed on day 7 after the treatment 
regimen was complete: retro-orbital sinus bleeds for percent 
HuRBC, percent muRetic level assessment, euthanasia, 
body weight measurements, and liver and spleen weight 
measurements.
Results and discussion
MTQ 
The ratio of excipients in experiments 2 and 6 (Table 1) 
favored the formation of clear and stable microemulsions 
with sizes below 20 nm as depicted in Table 4. The average 
size of microemulsion formulations where the oil was used 
without forming a clear and transparent emulsion was above 
100 nm with a broad size distribution which was attributed 
to low interaction of oil with the mixture of surfactants. 
The use of Tween 80 or Tween 20 did not result in a dif-
ference in TQ. Maximum solubility, as shown in Figure 1, 
which may have played a role in the sizes (below 20 nm) 
observed in experiments 2 and 6, were achieved when all 
the excipients were used as indicated in Table 1.
Table 3 Drug administration details per group
Group Drug Vehicle Dose (mg/kg) Frequency Route Treatment days
1 n=4 Vehicle control hecT N/a QD PO 3
2 n=4 PQ control PBs 25 QD PO 3
3 n=4 TQ hecT 5 QD PO 3
4 n=4 TQ hecT 1 QD PO 3
4 n=4 MTQ Microemulsion 10 QD PO 3
5 n=4 MTQ Microemulsion 5 QD PO 3
6 n=4 MTQ Microemulsion 1 QD PO 3
Note: PQ dose is expressed as the amount of base drug, not salt, given per kg of body weight. 
Abbreviations: hecT, 0.5% hydroxyethyl cellulose (w/v) and 0.2% Tween 80 (v/v); MTQ, microemulsion formulation of TQ; N/a, not applicable; PBs, phosphate-buffered 
saline; PO, oral gavage; PQ, primaquine; QD, daily; TQ, tafenoquine; v, volume; w, weight.
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Although the zeta potential values for experiments 2 and 
6 were not considered high enough (ie, -30 mV) (Table 4), 
the stability of the two microemulsions was quite acceptable. 
For most of the microemulsions, the pH values obtained 
were almost neutral (approximately pH 7). The conduc-
tivity values of all formulations were above 100 µS/cm, 
suggesting that all the microemulsions formed were of the 
o/w type, which is in agreement with the literature.31 The 
conductance of microemulsions is significantly increased 
with the percolation effect as droplets tend to fuse, thereby 
allowing enhanced transport of ions.32 Formulation 2 showed 
the lowest conductivity and formulation 7 the highest. For the 
latter, this could be attributed to a percolation effect relating 
to the size of droplets (>150 nm) and the high concentration 
of sodium oleate salt which may dissociate, resulting in an 
enhanced mobility of ions. Formulation 6 was chosen as the 
optimal formulation for pharmacokinetic studies because of 
its small droplet size and high conductivity value.
In vitro antiplasmodial assay 
There was no significant difference between the IC
50
 of RTQ 
and MTQ using the NF54 and Dd2 strains of P. falciparum . 
The mean IC
50
s (ng/mL) of RTQ and MTQ using NF54 
were 917.2 ng/mL and 671.7±452.83 ng/mL, respectively. 
Similarly, the IC
50
 (ng/mL) using the resistant Dd2 strain was 
495.9±192.76 for RTQ and 352.6±29.56 for MTQ.
The in vitro antiplasmodial activity of MTQ when com-
pared to that of RTQ in the Dd2 strain compares well with a 
previous report on the marked schizontocidal activity of TQ 
relative to CQ, mefloquine, cycloguanil, and pyrimethamine 
in regions with high percentages of multidrug-resistant para-
sites.33 This indicated that the microemulsion did not affect 
the inherent activity of TQ. 
In vivo pharmacokinetic study
Oral absorption study
Comparative results of the pharmacokinetic parameters are 
presented in Table 2. The whole blood profile obtained for 
the oral group is graphically presented in Figure 2. It is clear 
from Table 2 that the incorporation of TQ in the microemul-
sion (15–20 nm) produced promising results.
The observed maximum peak whole blood concentration 
was reached at approximately 9.0±1.0 hours in the RTQ 
formulation and at 6.5±1.5 hours for the MTQ formula-
tion. This reduction in time to peak concentration (C
max
) 
in the MTQ formulation could be as a result of a possible 
enhancement in absorption which translated to the significant 
increase in bioavailability of TQ (99%) when compared to 
the free drug (55%). This enhancement in bioavailability 
can be ascribed to enhanced solubility through formulation 
as a microemulsion. Furthermore, the apparent elimination 
half-life was 38.3±4.1 hours for the RTQ formulation and 
44.7±1.3 hours for the MTQ formulation, representing an 
approximate 6-hour increase in half-life between the RTQ 
and MTQ formulation. The C
max
 of TQ was greatly increased 
when incorporated into the microemulsion. RTQ had a C
max
 of 
3.06±0.37 µM, while a C
max 
of 5.28±0.26 µM was observed 
for the MTQ formulation. The area under the curve (AUC) 
0 to infinity of RTQ was 11,368±1,232 min⋅µmol/L, and the 
AUC 0 to infinity of MTQ was 23,842±872 min⋅µmol/L. As 
Table 4 characteristics of microemulsion formulations
Experiment number Size (nm) PDI ZP (mV) pH Conductivity, σ (µS/cm)
1 267.0±26.0 0.71±0.22 -14.1±1.5 7.5±0.4 160.8±1.1
2 10.7±0.6 0.30±0.13 -14.2±0.6 6.8±0.6 132.8±2.1
3 355.5±25.3 0.59±0.11 -27.2±2.3 8.0±0.2 172.4±2.3
4 70.5±4.2 1.0±0.0 -53.3±0.8 7.6±0.5 231.0±1.0
5 214.5±11.3 0.34±0.02 -40.2±1.7 7.3±0.6 159.4±1.4
6 11.1±0.8 0.27±0.02 -19.2±1.5 7.3±0.3 201.3±1.2
7 153.9±9.3 0.56±0.12 -49.7±2.1 7.6±0.7 291.3±0.6
8 129.0±7.2 0.37±0.54 -12.9±1.3 7.6±0.2 223.3±2.9
Abbreviations: PDI, polydispersity index; ZP, zeta potential.
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Figure 1 Percentage of TQ (of 5 mg/ml) dissolved in different components of 
microemulsion and the optimized microemulsion (n=3; mean ± standard deviation).
Abbreviations: PVa, polyvinyl alcohol; TQ, tafenoquine.
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Figure 2 Mean whole blood concentration versus time graphs following oral administration of 20 mg/kg each of tafenoquine reference formulation and microformulation. 
Note: Data shown represent mean ± standard error of the mean of n=4 mice. 
shown in Figure 1, the microemulsion increased the solubil-
ity of TQ by a factor of 16.2, 2.2, and 1.3 compared to 0.2% 
sodium oleate, 1% PVA, and the Tween mixture, respec-
tively. This suggests that more drug would be soluble in the 
MTQ microemulsion compared to the RTQ, and therefore 
be available for absorption or permeation. This solubility 
enhancement would likely play a critical role in enhancing 
the oral bioavailability of TQ.
Efficacy evaluation
In the present study, a significant enhancement in efficacy was 
observed at the concentrations (5 mg/kg and 1 mg/kg) of TQ 
in microemulsion used in the single-dose treatment of mice 
infected with P. berghei. The enhanced solubility and bio-
availability observed contributed to the recorded antimalarial 
activities of MTQ. A number of studies have demonstrated 
the advantages of drugs in nanoformulations over drugs that 
are not nanoformulated.34–38 Oral administration of curcumin-
loaded nanoparticles resulted in a cure in Plasmodium yoelii-
infected mice.39 Similarly, a recent study reported an enhanced 
in vivo efficacy of decoquinate nanoparticle formulations in 
mice.40 Futhermore, researchers have reported that nanostruc-
turesd lipid carriers and self-emulsifying systems increased 
the oral bioavailability of fenofibrate.41
Mice infected with P. berghei were treated with RTQ or 
MTQ at TQ doses of 1, 5, and 10 mg/kg. Although single-
dose treatment for this blood stage infection did not result in 
a cure, it was observed that, at the 10 mg/kg dose, the aver-
age parasitemia was 1% in both groups, indicating effective 
 killing at this level of TQ from both formulations. At the 
lower doses of 1 and 5 mg/kg TQ, there was a significant 
increase in the efficacy in the MTQ group, with average 
parasitemia levels approximately four- to tenfold lower 
than in the group treated with RTQ (average parasitemia of 
31.3% and 43.3% versus 7.4% and 3.1% for 1 and 5 mg/kg, 
respectively). 
The decrease in parasitemia at the 1 mg/kg dose can be 
explained by an elevated AUC of 1,288 from MTQ compared 
to 527 from RTQ. In contrast, however, the AUC at the 5 mg/kg 
dose was comparable, at 2,344 from RTQ and 2,331 from 
MTQ. The AUC appears to be linear with increases in dose 
for RTQ but not for MTQ. This suggests that the improved 
efficacy of TQ when given as an MTQ formulation against 
blood stage parasites may be due to other mechanisms in addi-
tion to the enhanced absorption. However, the current study 
did not evaluate the anti-hypnozoite activity of the MTQ.
g6PD toxicity evaluation
TQ is a promising drug for malaria prophylaxis;42 however, 
TQ has poor solubility and bioavailability and induces 
hemolysis in individuals with G6PD deficiency. In this study, 
the levels of hemolysis observed as indicated by the percent 
of HuRBC remaining at 7 days post-initiation of treatment 
are shown in Figure 3. The average percent loss of HuRBC 
recorded for PQ at 25 mg/kg dose (as a control) was 80.6%. 
RTQ was evaluated at 5 mg/kg and 1 mg/kg. Similarly, MTQ 
was evaluated at effective TQ doses of 5 mg/kg, 1 mg/kg, 
and 10 mg/kg. At 1 mg/kg and 5 mg/kg, the average percent 
International Journal of Nanomedicine 2015:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1500
Melariri et al









9HKLFOHFRQWURO 3ULPDTXLQH 74PJNJ 74PJNJ 074PJNJ 074PJNJ 074PJNJ
+
X5%
&V
UHP
DLQL
QJ
Figure 3 Percentage loss of hurBcs in scID mice following oral administration of unformulated TQ and MTQ (n=4) .
Abbreviations: HuRBC, human red blood cell; MTQ, microemulsion formulation of TQ; SCID, severe combined immunodeficiency; TQ, tafenoquine.
losses in HuRBC for RTQ and MTQ were comparable. 
However, it was interesting to observe that our 10 mg/kg of 
MTQ resulted in an average percent loss of HuRBC (62%) 
comparable to that of the 5 mg/kg dose of RTQ (59.9%). 
This suggests that the dose and efficacy of TQ could be 
increased in the MTQ from 5 mg/kg to 10 mg/kg without 
a corresponding increase in percentage loss of HuRBC in 
SCID mice with G6PD deficiency. RTQ showed clear dose 
dependence in hemolysis, with higher doses of drug resulting 
in a corresponding increase in RBC loss. 
Researchers have reported increased peripheral blood lev-
els in the bid to compensate acute blood loss, hence the reticu-
locytes could be an indicator for hemolytic toxicity.18 The 
muRetic level of the MTQ group was, therefore,  evaluated 
and was observed to be 1.5% and 0.8% for 5 mg/kg and 
1 mg/kg doses, respectively (Figure 4). The muRetic value 
was relatively high for 5 mg/kg TQ when compared to 5 mg/kg 
of nano-TQ, indicating increased blood levels suggesting 
an increase in hemolysis in SCID mice when dosed with 
5 mg/kg RTQ. It was also observed that the reticulocyte level 
in the group which received 10 mg/kg MTQ was 2.8%, and 
this compares well to the level of reticulocytes (2.5%) in the 
5 mg/kg RTQ group. 
Similarly, the spleen weight, which inevitably increases 
due to its role in destroying damaged red blood cells, was 
increased in the RTQ when compared to the nano-TQ (5 mg/kg 
and 1 mg/kg); however, the increase was not significant. The 
increase in the MTQ dose from 5 mg/kg to 10 mg/kg did not 
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Figure 4 Peripheral blood levels of muretics on day 7 (n=4).
Abbreviations: MTQ, microemulsion formulation of TQ; muretics, mouse reticulocytes; TQ, tafenoquine.
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result in a corresponding increase in spleen weight. There 
were no significant changes in pre- versus posttreatment body 
weights. The calculation of percent HuRBC loss recorded 
a trend indicating less hemolysis in the MTQ-treated mice 
compared to RTQ-treated mice (Figure 5).
RTQ and MTQ were comparatively evaluated post-oral 
administration, to assess mitigation of MTQ against dose-
dependent hemolysis on NOD SCID mice engrafted with 
A-G6PD-deficient HuRBCs. The hemolytic effect of test 
compounds and control were assessed by evaluating the 
percent loss of HuRBCs before (day 0) and after (day 7) 
drug administration. The treatment at doses of 10 mg/kg, 
5 mg/kg, and 1 mg/kg was administered daily for 3 days. 
The control drug PQ has been reported to cause a decline 
in HuRBCs after 3 days of treatment with PQ,18 and this 
was compared to a standard formulation of TQ (RTQ) and 
MTQ. The 3-day dosage of MTQ at 5 mg/kg and 1 mg/kg 
showed relatively less hemolysis when compared to RTQ in 
the NOD SCID mouse model engrafted with G6PD-deficient 
HuRBCs. The 10 mg/kg dose of MTQ resulted in HuRBC 
loss comparable to 5 mg/kg of RTQ. Similarly, 10 mg/kg 
MTQ upon evaluation of percentage muRetics, spleen 
enlargement, and liver weight recorded values comparable 
to 5 mg/kg RTQ. This showed that increasing the concentra-
tion of MTQ from 5 mg/kg to 10 mg/kg did not result in a 
corresponding increase in hemolysis or associated toxicity 
effects in SCID mice engrafted with A-G6PD-deficient 
HuRBCs. The differences in toxicity are attributed to the 
different kinetics of drug release occurring between RTQ 
and MTQ. Such differences in drug toxicity due to release 
kinetics have been observed previously.43 The results sug-
gest that microemulsions could be useful in reducing the 
hemolytic effect of RTQ, especially in G6PD-deficient 
individuals. In addition, comparing data from the efficacy 
and G6PD evaluation studies suggests that the dose can be 
further reduced to 1 mg/kg without loss of efficacy but with 
corresponding reduction in potential to cause hemolyis. 
This advancement could revitalize other 8-aminoquinolines 
as well as drugs for other diseases which induce oxidative 
stress in G6PD-deficient individuals. 
The solubility and bioavailability enhancement recorded 
via the application of the microemulsion delivery system 
could have contributed to the reduction in hemolysis 
observed in the NOD SCID mouse model engrafted with 
G6PD-deficient HuRBCs. Entrapping drug compounds in 
microemulsion could lead to a reduction in the toxicity effect 
of the therapeutic doses administered to patients. 
Conclusion
The results of this study provide evidence that the TQ 
microemulsion had the ability to enhance the solubil-
ity and therapeutic properties of TQ when administered 
orally. Furthermore, a significant enhancement in the oral 
bioavailability from 55% for RTQ to 99% using MTQ in 
healthy mice was observed. TQ doses administed as MTQ 
could be increased, without a corresponding increase in 
toxicity in SCID mice with G6PD deficiency. Future stud-
ies will evaluate MTQ for malaria prophylaxis in mice 
infected with P. berghei. The study could be designed 
to accommodate a 3-day treatment regimen used for the 
G6PD evaluation. The limitations of this study include 
the investigation of efficacy in C57/B76 mice, and toxic-
ity in NOD SCID mice. Since mice differ from humans, 
we may not directly extrapolate the findings to depict the 
situation in humans. 
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